Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells

Skin hyperpigmentation disorders arise due to excessive production of the macromolecular pigment melanin catalyzed by the enzyme tyrosinase. Recently, the therapeutic use of curcumin for inhibiting tyrosinase activity and production of melanin have been recognized, but poor stability and solubility...

Full description

Bibliographic Details
Main Authors: Shilpi Goenka, Francis Johnson, Sanford R. Simon
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/11/5/674
_version_ 1797535660559564800
author Shilpi Goenka
Francis Johnson
Sanford R. Simon
author_facet Shilpi Goenka
Francis Johnson
Sanford R. Simon
author_sort Shilpi Goenka
collection DOAJ
description Skin hyperpigmentation disorders arise due to excessive production of the macromolecular pigment melanin catalyzed by the enzyme tyrosinase. Recently, the therapeutic use of curcumin for inhibiting tyrosinase activity and production of melanin have been recognized, but poor stability and solubility have limited its use, which has inspired synthesis of curcumin analogs. Here, we investigated four novel chemically modified curcumin (CMC) derivatives (CMC2.14, CMC2.5, CMC2.23 and CMC2.24) and compared them to the parent compound curcumin (PC) for inhibition of in vitro tyrosinase activity using two substrates for monophenolase and diphenolase activities of the enzyme and for diminution of cellular melanogenesis. Enzyme kinetics were analyzed using Lineweaver-Burk and Dixon plots and nonlinear curve-fitting to determine the mechanism for tyrosinase inhibition. Copper chelating activity, using pyrocatechol violet dye indicator assay, and antioxidant activity, using a DPPH radical scavenging assay, were also conducted. Next, the capacity of these derivatives to inhibit tyrosinase-catalyzed melanogenesis was studied in B16F10 mouse melanoma cells and the mechanisms of inhibition were elucidated. Inhibition mechanisms were studied by measuring intracellular tyrosinase activity, cell-free and intracellular α-glucosidase enzyme activity, and effects on MITF protein level and cAMP maturation factor. Our results showed that CMC2.24 showed the greatest efficacy as a tyrosinase inhibitor of all the CMCs and was better than PC as well as a popular tyrosinase inhibitor-kojic acid. Both CMC2.24 and CMC2.23 inhibited tyrosinase enzyme activity by a mixed mode of inhibition with a predominant competitive mode. In addition, CMC2.24 as well as CMC2.23 showed a comparable robust efficacy in inhibiting melanogenesis in cultured melanocytes. Furthermore, after removal of CMC2.24 or CMC2.23 from the medium, we could demonstrate a partial recovery of the suppressed intracellular tyrosinase activity in the melanocytes. Our results provide a proof-of-principle for the novel use of the CMCs that shows them to be far superior to the parent compound, curcumin, for skin depigmentation.
first_indexed 2024-03-10T11:47:32Z
format Article
id doaj.art-c1f01c0612a34a3880af422698f5ae04
institution Directory Open Access Journal
issn 2218-273X
language English
last_indexed 2024-03-10T11:47:32Z
publishDate 2021-04-01
publisher MDPI AG
record_format Article
series Biomolecules
spelling doaj.art-c1f01c0612a34a3880af422698f5ae042023-11-21T17:57:33ZengMDPI AGBiomolecules2218-273X2021-04-0111567410.3390/biom11050674Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma CellsShilpi Goenka0Francis Johnson1Sanford R. Simon2Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794-5281, USADepartment of Chemistry, Stony Brook University, Stony Brook, NY 11790-3400, USADepartment of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794-5281, USASkin hyperpigmentation disorders arise due to excessive production of the macromolecular pigment melanin catalyzed by the enzyme tyrosinase. Recently, the therapeutic use of curcumin for inhibiting tyrosinase activity and production of melanin have been recognized, but poor stability and solubility have limited its use, which has inspired synthesis of curcumin analogs. Here, we investigated four novel chemically modified curcumin (CMC) derivatives (CMC2.14, CMC2.5, CMC2.23 and CMC2.24) and compared them to the parent compound curcumin (PC) for inhibition of in vitro tyrosinase activity using two substrates for monophenolase and diphenolase activities of the enzyme and for diminution of cellular melanogenesis. Enzyme kinetics were analyzed using Lineweaver-Burk and Dixon plots and nonlinear curve-fitting to determine the mechanism for tyrosinase inhibition. Copper chelating activity, using pyrocatechol violet dye indicator assay, and antioxidant activity, using a DPPH radical scavenging assay, were also conducted. Next, the capacity of these derivatives to inhibit tyrosinase-catalyzed melanogenesis was studied in B16F10 mouse melanoma cells and the mechanisms of inhibition were elucidated. Inhibition mechanisms were studied by measuring intracellular tyrosinase activity, cell-free and intracellular α-glucosidase enzyme activity, and effects on MITF protein level and cAMP maturation factor. Our results showed that CMC2.24 showed the greatest efficacy as a tyrosinase inhibitor of all the CMCs and was better than PC as well as a popular tyrosinase inhibitor-kojic acid. Both CMC2.24 and CMC2.23 inhibited tyrosinase enzyme activity by a mixed mode of inhibition with a predominant competitive mode. In addition, CMC2.24 as well as CMC2.23 showed a comparable robust efficacy in inhibiting melanogenesis in cultured melanocytes. Furthermore, after removal of CMC2.24 or CMC2.23 from the medium, we could demonstrate a partial recovery of the suppressed intracellular tyrosinase activity in the melanocytes. Our results provide a proof-of-principle for the novel use of the CMCs that shows them to be far superior to the parent compound, curcumin, for skin depigmentation.https://www.mdpi.com/2218-273X/11/5/674curcuminchemically modified curcumintyrosinaseenzyme kineticsmelanogenesisα-glucosidase
spellingShingle Shilpi Goenka
Francis Johnson
Sanford R. Simon
Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
Biomolecules
curcumin
chemically modified curcumin
tyrosinase
enzyme kinetics
melanogenesis
α-glucosidase
title Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
title_full Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
title_fullStr Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
title_full_unstemmed Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
title_short Novel Chemically Modified Curcumin (CMC) Derivatives Inhibit Tyrosinase Activity and Melanin Synthesis in B16F10 Mouse Melanoma Cells
title_sort novel chemically modified curcumin cmc derivatives inhibit tyrosinase activity and melanin synthesis in b16f10 mouse melanoma cells
topic curcumin
chemically modified curcumin
tyrosinase
enzyme kinetics
melanogenesis
α-glucosidase
url https://www.mdpi.com/2218-273X/11/5/674
work_keys_str_mv AT shilpigoenka novelchemicallymodifiedcurcumincmcderivativesinhibittyrosinaseactivityandmelaninsynthesisinb16f10mousemelanomacells
AT francisjohnson novelchemicallymodifiedcurcumincmcderivativesinhibittyrosinaseactivityandmelaninsynthesisinb16f10mousemelanomacells
AT sanfordrsimon novelchemicallymodifiedcurcumincmcderivativesinhibittyrosinaseactivityandmelaninsynthesisinb16f10mousemelanomacells